


Abstract summaries for EULAR

Discover some of the scientific data we are presenting this year at the Annual European Congress of Rheumatology (EULAR) Virtual Congress 2021. These abstracts have been adapted into plain language summaries to help increase understanding of complex data. Please note that abstract summaries only contain information from the full scientific abstract and selected supporting references. The results of these studies may not reflect those of other studies. Summaries are not intended to provide medical advice nor intended for promotional use.



The image shows a preview of a plain language media summary for a study titled 'The effect of secukinumab on non-radiographic axial spondyloarthritis at 2 years'. The summary is presented in a clean, professional layout with a blue header bar containing the text 'Plain Language Media Summary'. The Novartis logo is prominently displayed at the top right. The main title of the study is in bold black font. Below the title, the full abstract title is provided: 'Full abstract title: Secukinumab of Non-radiographic Axial Spondyloarthritis at 2 years'. The authors are listed as 'Authors: Poddubnyy D, Deodhar A', and the date is 'Date: June 2021'. A disclaimer note states: 'Please note that this summary only and selected supporting reference summary is not intended to provide'. The main content area features a blue silhouette of a person sitting in a chair, with a list of symptoms to their right: 'spinal pain', 'pain in the joints and back', 'fatigue', 'stiffness in the morning', and 'difficulty functioning in daily life'. The text above the list states: 'The symptoms of nr-axSpA and AS are comparable and include:'. Below the list, a paragraph explains: 'If left untreated, these symptoms can affect people's daily lives, and may limit their ability to participate in normal activities such as getting themselves ready in the morning, working and enjoying time with family.' Another paragraph at the bottom states: 'There are approximately 3.5 million patients with axSpA (1.7 million with nr-axSpA) in the top five European countries and US. The prevalence of axSpA in adults is similar to that of rheumatoid arthritis.'

The effect of secukinumab on non-radiographic axial spondyloarthritis at 2 years

A simplified overview of the abstract presented at EULAR June 2, 2021

[Read More \(PDF 0.3 MB\)](#)

Plain Language Media Summary

Secukinumab effect across the axial spondyloarthritis spectrum at 1 year

Full abstract title: Efficacy of Secukinumab in the Treatment of Axial Spondyloarthritis Spectrum over 1 Year: Results from a Phase 3 Clinical Trial

Authors: Magrey M, Walsh J, Huang J, et al.

Date: June 2021

Please note that this summary only covers the key findings of the abstract and selected supporting references. The summary is not intended to provide medical advice or to replace the full abstract.

Design of the study

```

graph LR
    A[1558 patients] --> B[6 clinical trials with secukinumab]
    B --> C[5 trials in AS]
    B --> D[1 trial in nr-axSpA]
    C --> E[1003 patients]
    D --> F[555 patients]
  
```

Secukinumab effect across the axial spondyloarthritis spectrum at 1 year

A simplified overview of the abstract presented at EULAR June 3, 2021.

[Open summary \(PDF 0.1 MB\)](#)

Plain Language Media Summary

Using sensitive ultrasound imaging to understand response of psoriatic arthritis to secukinumab over 24 weeks

Full abstract title: Responsiveness of Psoriatic Arthritis Treated with Secukinumab: Results from a Phase 3 Clinical Trial

Authors: Boers M, Conaghan PG, Scolding S, et al.

Date: June 2021

Please note that this summary only covers the key findings of the abstract and selected supporting references. The summary is not intended to provide medical advice or to replace the full abstract.

The six key "domains" of PsA:³

Domain	Percentage of PsA patients
Joints	About 80% of PsA patients have skin symptoms prior to developing joint symptoms ¹
Skin	40-50% of PsA patients may have dactylitis ²
Dactylitis	30-50% of PsA patients may have enthesitis ³
Enthesitis	38% of PsA patients may have nail psoriasis ⁴
Nail	Up to 70% of PsA patients are impacted by axial involvement ⁵
Axial involvement	

Doctors use different innovative and sensitive imaging techniques to visualize inflammation inside the body, such as magnetic resonance imaging (MRI) and Power Doppler ultrasound (PDUS) scans. PDUS can be used in PsA patients to detect early, smaller changes that may not otherwise be identified and thus can identify disease changes more sensitively.

Using sensitive ultrasound imaging to understand response of psoriatic arthritis to secukinumab over 24 weeks

A simplified overview of the abstract presented at EULAR June 4, 2021.

[Open summary \(PDF 0.2 MB\)](#)


Secukinumab seen in children

Full abstract title: Efficacy and Safety of Secukinumab in Children with Psoriatic Arthritis: Primary Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Authors: Ruperto N, Foeldvari I, et al.

Date: June 2021

Please note that this summary or abstract is for informational purposes only and selected supporting references are not intended to provide a full overview of the study.



Secukinumab effect in two types of arthritis seen in children and adolescents at two years

A simplified overview of the abstract presented at EULAR June 5, 2021.

[Open summary \(PDF 0.1 MB\)](#)

Source URL: <https://prod1.novartis.com/healthcare-professionals/medical-congresses-and-events/abstract-summaries-eular>

List of links present in page

1. <https://prod1.novartis.com/healthcare-professionals/medical-congresses-and-events/abstract-summaries-eular>
2. https://prod1.novartis.com/sites/novartis_com/files/effect-of-secukinumab-on-non-radiographic-axial-spondyloarthritis-at-2-years.pdf
3. https://prod1.novartis.com/sites/novartis_com/files/secukinumab-effect-across-the-axial-spondyloarthritis-spectrum-at-1-year.pdf
4. https://prod1.novartis.com/sites/novartis_com/files/using-sensitive-ultrasound-imaging-to-understand-response-of-psoriatic-arthritis-to-secukinumab-over-24-weeks.pdf
5. https://prod1.novartis.com/sites/novartis_com/files/secukinumab-effect-in-two-types-of-arthritis-seen-in-children-and-adolescents-at-two-years.pdf